| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/17/1998 | US5719149 Morpholine derivatives and their use as therapeutic agents |
| 02/17/1998 | US5719143 Polysubstituted 3-acylamino-5-phenyl-1, 4-benzodiazepin-2-one derivatives, process for their preparation and the pharmaceutical compositions containing them |
| 02/17/1998 | US5719140 2, 3-, 4-, 5-, 6-, 7-, 8-, 9- and /or 10-substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use |
| 02/17/1998 | US5719137 Method of preventing neurodegeneration and cognitive dysfunction using 17α-dihydroequilenin |
| 02/17/1998 | US5719129 Sunscreen agents, antiaging agent, free radical scavenger |
| 02/17/1998 | CA2101252C Process for preparing trans-piperidine-2,5- dicarboxylates |
| 02/12/1998 | WO1998005780A2 Voltage-gated calcium channel antagonist and methods |
| 02/12/1998 | WO1998005776A2 Secreted proteins and polynucleotides encoding them |
| 02/12/1998 | WO1998005775A1 Gene involved in cadasil, method of diagnosis and therapeutic application |
| 02/12/1998 | WO1998005661A1 Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives |
| 02/12/1998 | WO1998005660A1 Pyrrolo(3,2-c) quinoline derivatives |
| 02/12/1998 | WO1998005648A1 Novel isoquinoline derivatives |
| 02/12/1998 | WO1998005353A1 hCG AND DERIVATIVES AS MATRIX METALLOPROTEASES INHIBITORS |
| 02/12/1998 | WO1998005350A1 Materials and methods for treatment of plaquing diseases |
| 02/12/1998 | WO1998005343A1 Anti-stress drugs and functional foods having anti-stress effects |
| 02/12/1998 | WO1998005335A1 PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IλB-$g(a) |
| 02/12/1998 | WO1998005333A1 Use of beta-sheet mimetics as protease and kinase inhibitors and as inhibitors of transcription factors |
| 02/12/1998 | WO1998005330A1 Treatment of psychotic disorders |
| 02/12/1998 | WO1998005328A1 Il-8 receptor antagonists |
| 02/12/1998 | WO1998005326A1 Method for treating nicotine withdrawal |
| 02/12/1998 | WO1998005325A1 Method for treating disruptive behavior disorders |
| 02/12/1998 | WO1998005324A1 Method for treating bipolar disorder |
| 02/12/1998 | WO1998005317A1 Il-8 receptor antagonists |
| 02/12/1998 | WO1998005292A2 Piperidine and piperazine derivatives and their use as muscarinic antagonists |
| 02/12/1998 | WO1998005291A2 Method for treating mental retardation |
| 02/12/1998 | WO1998005208A1 Method for treating substance abuse |
| 02/12/1998 | WO1998005207A1 Method for treating excessive aggression |
| 02/12/1998 | CA2262900A1 Use of beta-sheet mimetics as protease and kinase inhibitors and as inhibitors of transcription factors |
| 02/12/1998 | CA2262753A1 Voltage-gated calcium channel antagonist and methods |
| 02/12/1998 | CA2262614A1 Method for treating disruptive behavior disorders |
| 02/12/1998 | CA2262612A1 Method for treating mental retardation |
| 02/12/1998 | CA2262459A1 Gene involved in cadasil, method of diagnosis and therapeutic application |
| 02/12/1998 | CA2262399A1 Secreted proteins and polynucleotides encoding them |
| 02/12/1998 | CA2262223A1 Novel carbocyclic diarylmethylene derivatives, methods for preparing same, and therapeutical uses thereof |
| 02/12/1998 | CA2261946A1 Method for treating nicotine withdrawal |
| 02/12/1998 | CA2261942A1 Method for treating substance abuse |
| 02/12/1998 | CA2261783A1 1,2-diarylindole as cox-2 inhibitors |
| 02/12/1998 | CA2261676A1 Method for treating excessive aggression |
| 02/12/1998 | CA2233987A1 Materials and methods for treatment of plaquing diseases |
| 02/11/1998 | EP0822983A1 Apopain |
| 02/11/1998 | EP0822934A1 Antithrombotic amidinotetrahydropyridylalanine derivatives |
| 02/11/1998 | EP0822832A1 Cd45rb binding compounds for the prevention of transplant rejection |
| 02/11/1998 | EP0822829A1 Use of glial neurotrophic factor (gdnf) for treatment of hearing disorders |
| 02/11/1998 | EP0822828A1 Isolated 55 to 75 kda protein which binds to prion protein |
| 02/11/1998 | EP0822823A1 Anionic oxygen radicals containing therapeutic agents and their use in pain relief |
| 02/11/1998 | EP0822813A1 A combination of a 5-ht uptake inhibitor with a selective 5-ht 1a? antagonist |
| 02/11/1998 | EP0776323B1 Salts of an anti-migraine indole derivative |
| 02/11/1998 | EP0624164B1 Peptides with organo-protective activity, process for their preparation and their use in the therapy |
| 02/11/1998 | EP0538248B1 Tetrahydroisoquinolinylcarbamates of 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo [2,3-b]indole |
| 02/11/1998 | CN1173181A Pregnanes and cholanes as neurochemical initiators of change in hypothalamic function |
| 02/11/1998 | CN1173174A Substituted oxazolidine calpain and/or cathepsin B inhibitors |
| 02/11/1998 | CN1173135A Use of bioassimilable boron compounds for the control of subviral pathogenic agents |
| 02/11/1998 | CN1173134A Use of incense in the treatment of alzheimer's disease |
| 02/11/1998 | CN1173132A Dihydropyrimidines and uses thereof |
| 02/10/1998 | US5717102 Psychotherapeutics; headaches |
| 02/10/1998 | US5716991 Pharmaceutical compositions comprising paracetamol and L-cysteine or a precursor thereof |
| 02/10/1998 | US5716979 Tachykinin antagonists |
| 02/10/1998 | US5716975 Nontoxic rhodanine derivatives; antidiabetic agents, cathepsin d inhibitors, b-amyloid protein reduction |
| 02/10/1998 | US5716959 Administering substituted piperazines having hydroxy- or amino-alkyl groups on one nitrogen and carboxylic, phosphoric or sulfonic alkyl groups on the other nitrogen, for treatment of cancer and autoimmune diseases |
| 02/10/1998 | US5716956 Dihydrophthalazine antagonists of excitatory amino acid receptors |
| 02/10/1998 | US5716955 Cytokine inhibitor |
| 02/10/1998 | US5716953 Modifiers of gastrin and cholecystokinins |
| 02/10/1998 | US5716949 Heterocyclic compounds |
| 02/10/1998 | US5716946 Multiple sclerosis treatment |
| 02/10/1998 | US5716942 Treatment of migraine with morpholine tachykinin receptor antagonists |
| 02/10/1998 | US5716936 Pyrrolidine derivatives for the treatment of cholecystokinine and gastrine-related disorders |
| 02/10/1998 | US5716930 Polypeptide from genetically engineered cells |
| 02/10/1998 | US5716929 Inhibitors of interleukin-1β converting enzyme |
| 02/10/1998 | US5716609 Therapeutic anti-inflammatory and analgesic composition containing nimesulide for use transdermally and a process for the manufacture thereof |
| 02/10/1998 | CA1339661C Cycloalkylamides of (8b)-1alkyl-6 (substituted)ergolines |
| 02/05/1998 | WO1998004726A1 Hsv strain lacking functional icp27 and icp34.5 genes |
| 02/05/1998 | WO1998004714A1 A NOVEL HUMAN mRNA EDITING ENZYME |
| 02/05/1998 | WO1998004694A2 Secreted proteins and polynucleotides encoding them |
| 02/05/1998 | WO1998004688A1 Egf-like factor from chromaffin granules and glia cell-derived neurotrophic factor with survival-promoting activity on daergic neurons |
| 02/05/1998 | WO1998004560A1 SUBSTITUTED TRIAZOLO PYRIDAZINE DERIVATIVES AS INVERSE AGONISTS OF THE GABAAα5 RECEPTOR SUBTYPE |
| 02/05/1998 | WO1998004559A2 Substituted triazolo-pyridazine derivatives as ligands for gaba receptors |
| 02/05/1998 | WO1998004556A1 Pyridazino [4,5-b]-quinoline 5-oxide derivatives, their preparation and their use as glycine antagonists |
| 02/05/1998 | WO1998004527A1 Pyranoindole and carbazole inhibitors of cox-2 |
| 02/05/1998 | WO1998004526A1 SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
| 02/05/1998 | WO1998004289A2 Pharmaceutical composition containing a 5ht2c antagonist and a d2 antagonist |
| 02/05/1998 | WO1998004258A1 Formulation for the treatment and/or prophylaxis of dementia |
| 02/05/1998 | WO1998004249A2 Tramadol multiple unit formulations |
| 02/05/1998 | WO1998004135A1 Diphenyl heterocycles as potassium channel modulators |
| 02/05/1998 | WO1997047744A3 T-cell selective interleukin-4 agonists |
| 02/05/1998 | WO1997038084A3 Polynucleotides derived from a pbmc cdna library encoding secreted proteins |
| 02/05/1998 | CA2261813A1 Pharmaceutical composition containing a 5ht2c antagonist and a d2 antagonist |
| 02/05/1998 | CA2261588A1 Pyranoindole and carbazole inhibitors of cox-2 |
| 02/05/1998 | CA2261581A1 Secreted proteins and polynucleotides encoding them |
| 02/05/1998 | CA2261233A1 Formulation for the treatment and/or prophylaxis of dementia |
| 02/05/1998 | CA2261167A1 Substituted sulfonamides as selective .beta.3 agonists for the treatment of diabetes and obesity |
| 02/05/1998 | CA2260900A1 Substituted triazolo pyridazine derivatives as inverse agonists of the gabaa.alpha.5 receptor subtype |
| 02/05/1998 | CA2260740A1 A novel human mrna editing enzyme |
| 02/04/1998 | EP0822199A2 N-terminally monopegylated polypeptides and process for their preparation. |
| 02/04/1998 | EP0822190A1 Phenyl heterocycles as cyclooxygenase-2 inhibitors |
| 02/04/1998 | EP0822182A1 Substituted indanylidineacetylguanidines as Na+/H+ exchange inhibitors, process for their preparation, their use as medicaments or diagnostic agents and medicaments containing them |
| 02/04/1998 | EP0821964A2 Use of adenosine and adenosine derivatives for analgesia and attenuation of stress or stress responses |
| 02/04/1998 | EP0821960A1 Use of xanthine derivatives for the modulation of apoptosis |
| 02/04/1998 | EP0821959A2 Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine for treating nicotine withdrawal |
| 02/04/1998 | EP0821958A2 Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating excessive aggression |
| 02/04/1998 | EP0821957A2 Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse |